DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venkataramanan, R.
Right arrow Articles by Strom, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venkataramanan, R.
Right arrow Articles by Strom, S. C.

Vol. 28, Issue 11, 1270-1273, November 2000

SHORT COMMUNICATION
Milk Thistle, a Herbal Supplement, Decreases the Activity of CYP3A4 and Uridine Diphosphoglucuronosyl Transferase in Human Hepatocyte Cultures

Raman Venkataramanan, Vinod Ramachandran, Bernard J. Komoroski, Shimin Zhang, Paul L. Schiff, and Stephen C. Strom

Department of Pharmaceutical Sciences
School of Pharmacy (R.V., V.R., B.J.K., S.Z., P.S.)
Department of Pathology
School of Medicine (R.V., S.C.S.)
University of Pittsburgh
Pittsburgh, Pennsylvania

Milk thistle extract is one of the most commonly used nontraditional therapies, particularly in Germany. Milk thistle is known to contain a number of flavonolignans. We evaluated the effect of silymarin, on the activity of various hepatic drug-metabolizing enzymes in human hepatocyte cultures. Treatment with silymarin (0.1 and 0.25 mM) significantly reduced the activity of CYP3A4 enzyme (by 50 and 100%, respectively) as determined by the formation of 6-beta -hydroxy testosterone and the activity of uridine diphosphoglucuronosyl transferase (UGT1A6/9) (by 65 and 100%, respectively) as measured by the formation of 4-methylumbelliferone glucuronide. Silymarin (0.5 mM) also significantly decreased mitochondrial respiration as determined by MTT reduction in human hepatocytes. These observations point to the potential of silymarin to impair hepatic metabolism of certain coadministered drugs in humans. Indiscriminate use of herbal products may lead to altered pharmacokinetics of certain drugs and may result in increased toxicity of certain drugs.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Integr Cancer TherHome page
J. Post-White, E. J. Ladas, and K. M. Kelly
Advances in the Use of Milk Thistle (Silybum marianum)
Integr Cancer Ther, June 1, 2007; 6(2): 104 - 109.
[Abstract] [PDF]

Home page
 Integr Cancer TherHome page
D. J. Kroll, H. S. Shaw, and N. H. Oberlies
Milk Thistle Nomenclature: Why It Matters in Cancer Research and Pharmacokinetic Studies
Integr Cancer Ther, June 1, 2007; 6(2): 110 - 119.
[Abstract] [PDF]

Home page
 Nutr Clin PractHome page
S. Saadeh
Nonalcoholic Fatty Liver Disease and Obesity
Nutr Clin Pract, February 1, 2007; 22(1): 1 - 10.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Meijerman, J. H. Beijnen, and J. H.M. Schellens
Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction
Oncologist, July 1, 2006; 11(7): 742 - 752.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. Gurley, M. A. Hubbard, D. K. Williams, J. Thaden, Y. Tong, W. B. Gentry, P. Breen, D. J. Carrier, and S. Cheboyina
Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin
J. Clin. Pharmacol., February 1, 2006; 46(2): 201 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. P.H. van Erp, S. D. Baker, M. Zhao, M. A. Rudek, H.-J. Guchelaar, J. W.R. Nortier, A. Sparreboom, and H. Gelderblom
Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan
Clin. Cancer Res., November 1, 2005; 11(21): 7800 - 7806.
[Abstract] [Full Text] [PDF]

Home page
 Nutr Clin PractHome page
J. Boullata
Natural Health Product Interactions with Medication
Nutr Clin Pract, February 1, 2005; 20(1): 33 - 51.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Sparreboom, M. C. Cox, M. R. Acharya, and W. D. Figg
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
J. Clin. Oncol., June 15, 2004; 22(12): 2489 - 2503.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Sridar, T. C. Goosen, U. M. Kent, J. A. Williams, and P. F. Hollenberg
SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES
Drug Metab. Dispos., June 1, 2004; 32(6): 587 - 594.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.